Elbasvir/Grazoprevir (Zepatier) for Hepatitis C

Date: February 29, 2016 Issue #: 1489 Summary: The FDA has approved Zepatier (Merck), a fixed-dose combination of two direct-acting antiviral agents — elbasvir, an NS5A inhibitor, and grazoprevir, an NS3/4A protease inhibitor — for oral treatment of chronic hepatitis C virus (HCV) genotype 1 or 4 infection.

http://secure.medicalletter.org/TML-article-1489a

Source: The Medical Letter - February 10, 2016 Category: Drugs & Pharmacology Authors: admin Tags: boceprevir daclatasvir Daklinza Efavirenz elbasvir Galexos grazoprevir Harvoni Hepatitis C Holkira Pak ledipasvir Olysio ombitasvir paritaprevir Ribavirin Ritonavir simeprevir sofosbuvir Sovaldi Technivie telaprevir Source Type: research